Buyukozkan*, Alvarez-Mulett* , et.al., iScience (2022), sought to define the metabolomic and proteomic signatures of COVID-19, and to explore interactions between metabolites and proteins that can serve as a roadmap for future mechanistic studies. The study furthermore proposed a novel clinical composite outcome score that could be used in clinical prediction models for COVID-19.
Batra*, Whalen*, et.al., PLOS Pathogens (2022), describes a first report on the molecular comparison between two ARDS etiologies – COVID-19 and bacterial sepsis. This study is a step toward solving two pertinent clinical challenges associated with ARDS: the identification of novel therapeutic options, and the delineation of heterogeneous pathophysiological manifestations within ARDS groups .
Batra*, Uni*, et.al., Molecular Medicine (2023), describes a first urine-based multi-omic analysis of COVID-19 ARDS compared to bacterial sepsis-induced ARDS. This analysis shows molecular similarities and differences between the two ARDS groups. The most striking finding was a proteomics-based mortality signature specifically for COVID-19 ARDS, which will require further investigation as a potential early biomarker for mortality.